ArcherDX announces strategic collaboration with AstraZeneca to develop personalized cancer monitoring assays

ArcherDX announces strategic collaboration with AstraZeneca to develop personalized cancer monitoring assays

BOULDER -- ArcherDX, Inc. , today announced a strategic collaboration with AstraZeneca to develop assays to support multiple planned Phase 3 clinical trials for AstraZeneca's targeted... Read More

Tuesday May 26, 2020 0 comments Tags: Boulder, ArcherDx, AstraZeneca, Jason Myers

ArcherDX and Bayer announce global collaboration to develop next-gen sequencing-based companion diagnostic for VITRAKVI

ArcherDX and Bayer announce global collaboration to develop next-gen sequencing-based companion diagnostic for VITRAKVI

BOULDER/BERLIN -- ArcherDX and Bayer today announced a global collaboration for the development and commercialization of a next-generation sequencing (NGS)-based companion diagnostic (CDx) for... Read More

Thursday May 14, 2020 0 comments Tags: Boulder, ArcherDx, Jason Myers, Bayer

ArcherDX appoints Jason Ryan to board of directors

ArcherDX appoints Jason Ryan to board of directors

BOULDER -- ArcherDX, Inc. has appointed Jason Ryan, chief operating and financial officer at Magenta Therapeutics and former chief financial officer at Foundation Medicine, to the company's board... Read More

Monday May 11, 2020 0 comments Tags: Boulder, ArcherDx, Jason Ryan, Jason Myers, Steve Kafka

ArcherDX and Premier Inc. partner to deliver personalized genomic testing to patients

ArcherDX and Premier Inc. partner to deliver personalized genomic testing to patients

BOULDER -- ArcherDX, Inc. and Premier Inc. , a leading healthcare improvement company,announced they have signed a two-part agreement, kicking off a multi-year program. Premier Applied... Read More

Tuesday April 21, 2020 0 comments Tags: Boulder, ArcherDx, Jason Myers, Premier Inc.

ArcherDX receives approval for Archer®MET Companion Diagnostic in advanced non-small cell lung cancer in Japan

ArcherDX receives approval for Archer®MET Companion Diagnostic in advanced non-small cell lung cancer in Japan

BOULDER -- ArcherDX, Inc. announced its ArcherMET companion diagnostic (CDx) has been approved by the Japanese Ministry of Health, Labour and Welfare and the Pharmaceutical Medical Devices Agency... Read More

Wednesday March 25, 2020 0 comments Tags: Boulder, ArcherDx, ArcherMET, Jason Myers

ArcherDX Personalized Cancer Monitoring (PCM) tech designated by FDA as Breakthrough Device

ArcherDX Personalized Cancer Monitoring (PCM) tech designated by FDA as Breakthrough Device

BOULDER -- ArcherDX, Inc. announced it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Personalized Cancer Monitoring (PCM) technology, a... Read More

Wednesday January 15, 2020 0 comments Tags: Boulder, ArcherDx, Jason Myers, FDA

ArcherDX and Illumina partner to broaden access for oncology testing

ArcherDX and Illumina partner to broaden access for oncology testing

BOULDER -- ArcherDX, Inc . announced a non-exclusive, multi-year partnership with San Diego-based Illumina, Inc. (NASDAQ: ILMN) that aims to broaden access of next generation sequencing (NGS)-based... Read More

Monday January 13, 2020 0 comments Tags: Boulder, ArcherDx, Jason Myers, Illumina, Phil Febbo

ArcherDX appoints Mark Massaro company CFO

ArcherDX appoints Mark Massaro company CFO

BOULDER -- ArcherDX, Inc. , a molecular diagnostics company developing breakthrough solutions to advance and enable the practice of personalized genomic medicine, today announced Mark Massaro has... Read More

Tuesday January 7, 2020 0 comments Tags: Boulder, ArcherDx, Mark Massaro, Jason Myers